This early-phase study tests a new imaging drug called [18F]MK-0947 that works with PET scans to show where a protein called α-synuclein builds up in the brain—a hallmark of Parkinson's disease. Researchers will check safety and how well the tracer works in 22 adults (some with P…
Phase: EARLY_PHASE1 • Sponsor: Invicro • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC